← Back to patent-cliff list
Levosimendan
Tier C — Watch / tradeLevosimendan
Orion Corporation
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Potassium channel, VGKCs, PDE3, Troponin, cardiac muscle
Brand：Simdax
Indications (approved)：Heart failure
Regional status
US
Phase III
2002-09-01
EU
Approved
2000-09-22
China
Approved
2010-04-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Levosimendan?
Approved indications include: Heart failure.
When does the Levosimendan patent expire?
No public expiry year is available for Levosimendan yet; this page updates once verified.
How do I get a quote for Levosimendan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27